No Resistance to Tenofovir Disoproxil Fumarate Through 96 Weeks of Treatment in Patients With Lamivudine-Resistant Chronic Hepatitis B

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 12, 2014, Pages 2106-2112.e1

  Corsa, Amoreena C ^a   Liu, Yang ^a   Flaherty, John F ^a   Mitchell, Ben ^a   Fung, Scott K ^b   Gane, Edward ^c   Miller, Michael D ^a   Kitrinos, Kathryn M ^a  

^a GILEAD SCIENCES   (United States)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Adefovir; Entecavir; Hepatitis B Virus; Resistance

Indexed keywords

ADEFOVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR DISOPROXIL; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; STRUCTURAL GENE; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CHEMISTRY; DNA SEQUENCE; DRUG COMBINATION; ENZYMOLOGY; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; POINT MUTATION; VIROLOGY;

ADENINE; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; ORGANOPHOSPHONATES; POINT MUTATION; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA;

EID: 84918778702     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.05.024     Document Type: Article

References (33)

1. Pan C.Q., Hu K.Q., Tsai N. Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients. Antivir Ther 2013, 18:841-852.
2. Zoulim F., Locarnini S. Management of treatment failure in chronic hepatitis B. JHepatol 2012, 56(Suppl 1):S112-S122.
3. Lok A.S.F., Lai C.-L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714-1722.
4. Fasano M., Lampertico P., Marzano A., et al. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. JHepatol 2012, 56:1254-1258.
5. Liaw Y.-F., Sung J.J.Y., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. NEngl J Med 2004, 351:1521-1531.
6. EASL clinical practice guidelines: management of chronic hepatitis Bvirus infection. JHepatology 2012, 57:167-185. European Association for the Study of the Liver (EASL), [published version].
7. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
8. Liaw Y.F., Kao J.H., Piratvisuth T., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012, 6:531-561.
9. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:1-36.
10. Lampertico P., Vigano M., Manenti E., et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005, 42:1414-1419.
11. Lampertico P., Vigano M., Manenti E., et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007, 133:1445-1451.
12. Fung S.K., Chae H.B., Fontana R.J., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. JHepatol 2006, 44:283-290.
13. Ha M., Zhang G., Diao S., et al. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy. Intern Med 2012, 51:1509-1515.
14. Tenney D.J., Rose R.E., Baldick C.J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49:1503-1514.
15. Marcellin P., Heathcote E., Buti M., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. NEngl J Med 2008, 359:2442-2455.
16. Kitrinos K.M., Corsa A., Liu Y., et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014, 59:434-442.
17. Delaney W.E., Ray A.S., Yang H., et al. Intracellular metabolism and invitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006, 50:2471-2477.
18. Lada O., Benhamou Y., Cahour A., et al. Invitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antiviral Therapy 2004, 9:353-363.
19. Hann H.W., Chae H.B., Dunn S.R. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol Int 2008, 2:244-249.
20. Kuo A., Dienstag J.L., Chung R.T. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004, 2:266-272.
21. van Bommel F., de Man R.A., Wedemeyer H., et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010, 51:73-80.
22. Patterson S.J., George J., Strasser S.I., et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011, 60:247-254.
23. Fung S., Kwan P., Fabri M., et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2014, 146:980-988.
24. Murray K.F., Szenborn L., Wysocki J., et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012, 56:2018-2026.
25. Zhu Y., Curtis M., Borroto-Esoda K. HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays. JVirol Methods 2011, 173:340-346.
26. Yuen M.F., Lai C.L. Treatment of chronic hepatitis B: evolution over two decades. JGastroenterol Hepatol 2011, 26(Suppl 1):138-143.
27. Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis duringtreatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013, 381:468-475.
28. Tenney D.J., Rose R.E., Baldick C.J., et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007, 51:902-911.
29. Berg T., Zoulim F., Moeller B., et al. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. JHepatol 2014, 60:715-722.
30. Gordon S.C., Krastev Z., Horban A., et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 2013, 58:505-513.
31. Lok A.S., Trinh H., Carosi G., et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012, 143:619-628.
32. Wong G.L., Chan H.L., Chan H.Y., et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013, 144:933-944.
33. Zoutendijk R., Reijnders J.G., Zoulim F., et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013, 62:760-765.